Efficacy and pharmacogenomic biomarkers in breast cancer

Biomarkers in Medicine

Volumn 6, Issue 2, 2012, Pages 211-221

  Paul, Asit K ^a   Schwab, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

biomarker; breast cancer; efficacy biomarker; pharmacogenomics; prediction; toxicity biomarker; treatment response

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE; BIOLOGICAL MARKER; CAPECITABINE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIHYDROPYRIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOXETINE; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; NERATINIB; PAROXETINE; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CHROMOGENIC IN SITU HYBRIDIZATION; CIRCULATING TUMOR CELL; CLINICAL EXAMINATION; DISEASE FREE SURVIVAL; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEART DISEASE; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BREAST NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; PHARMACOGENETICS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859068828     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.7     Document Type: Review

References (90)

1. Hayes DF. Contribution of biomarkers to personalized medicine. Breast Cancer Res. 12(Suppl. 4), S3 (2010).
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
3. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88(20), 1456-1466 (1996).
4. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005).
5. Febbo PG, Ladanyi M, Aldape KD et al. NCCN Task Force Report: evaluating the clinical utility of tumor markers in oncology. J. Natl Compr. Canc. Netw. 9(Suppl. 5), S1-S32 (2011).
6. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287-5312 (2007).
7. Napieralski R, Brünner N, Mengele K, Schmitt M. Emerging biomarkers in breast cancer care. Biomarkers Med. 4(4), 505-522 (2010).
8. Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189(4204), 726-727 (1975).
9. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 6(4), 195-197 (2010).
10. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J. Clin. Oncol. 29(15), E458 (2011).
11. Allred DC, Carlson RW, Berry DA et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J. Natl Compr. Canc. Netw. 7(Suppl. 6), S1-S21; quiz S22-S23 (2009).
12. Dowsett M, Salter J, Zabaglo L et al. Predictive algorithms for adjuVant therapy: TransATAC. Steroids 76(8), 777-780 (2011).
13. Balleine RL, Hunt SM, Clarke CL. Coexpression of alternatively spliced estrogen and progesterone receptor transcripts in human breast cancer. J. Clin. Endocrinol. Metab. 84(4), 1370-1377 (1999).
14. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J. Clin. Oncol. 14(10), 2843-2877 (1996).
15. Duffy MJ. Estrogen receptors: role in breast cancer. Crit. Rev. Clin. Lab. Sci. 43(4), 325-347 (2006).
16. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 94(3), 370-383 (2008).
17. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical AdjuVant Breast and Bowel Project Experience. Semin. Oncol. 28(4), 400-418 (2001).
18. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351(9114), 1451-1467 (1998).
19. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuVant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97(17), 1262-1271 (2005).
20. Valavaara R. Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Williston Park), 11(5 Suppl. 4), 14-18 (1997).
21. McGuire WL. Current status of estrogen receptors in human breast cancer. Cancer 36(2), 638-644 (1975).
22. Dowsett M, Houghton J, Iden C et al. Benefit from adjuVant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17(5), 818-826 (2006
23. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuVant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21(10), 1973-1979 (2003
24. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent adVances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res. 11(2), 205 (2009
25. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65(10-11), 825-830 (2000
26. Badwe R, Hawaldar R, Parmar V et al. Singleinjection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J. Clin. Oncol. 29(21), 2845-2851 (2011
27. Chaudhry A, Puntis ML, Gikas P, Mokbel K. Does the timing of breast cancer surgery in pre-menopausal women affect clinical outcome? An update. Int. Semin. Surg. Oncol. 3, 37 (2006
28. Samuel M, Wai KL, Brennan VK, Yong WS. Timing of breast surgery in premenopausal breast cancer patients. Cochrane Database Syst. Rev. 5, CD003720 (2011
29. Asselin-Labat ML, Vaillant F, Sheridan JM et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010
30. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717), 974-976 (1985
31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987
32. Gabos Z, Sinha R, Hanson J et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol. 24(36), 5658-5663 (2006
33. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007
34. Carlson RW, Moench SJ, Hammond ME et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J. Natl Compr. Canc. Netw. 4(Suppl. 3), S1-S22; quiz S23-S24 (2006
35. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27(8), 1323-1333 (2009
36. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7(2), 98-107 (2010
37. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 135(1), 55-62 (2011
38. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuVant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005
39. Eiermann W; International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2- positive metastatic breast cancer: pivotal trial data. Ann. Oncol. 12(Suppl. 1), S57-S62 (2001
40. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2- amplified breast cancer cell lines. Ann. Oncol. 21(2), 255-262 (2010
41. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2), 117-127 (2004
42. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2- positive adVanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006
43. Blackwell KL, Pegram MD, Tan-Chiu E et al. Single-agent lapatinib for HER2- overexpressing adVanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20(6), 1026-1031 (2009
44. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96(12), 926-935 (2004
45. Johnston S, Pippen J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27(33), 5538-5546 (2009
46. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 26(7), 1059-1065 (2008
47. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM study. J. Clin. Oncol. 27(33), 5529-5537 (2009
48. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357(15), 1496-1506 (2007
49. Järvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156(3), 839-847 (2000
50. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracyclinebased adjuVant chemotherapy in HER-2/ neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24(16), 2428-2436 (2006
51. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 109(2), 209-229 (2008
52. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuVant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100(1), 14-20 (2008
53. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29(7), 859-867 (2011
54. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009
55. Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A. Prognostic applications of gene expression signatures in breast cancer. Oncology 77(Suppl. 1), 2-8 (2009
56. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
57. Van De Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
58. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
59. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55-65 (2010).
60. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).
61. Buyse M, Loi S, Van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006).
62. Bueno-de-Mesquita JM, Van Harten WH, Retel VP et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 8(12), 1079-1087 (2007).
63. Knauer M, Cardoso F, Wesseling J et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br. J. Cancer 103(12), 1788-1793 (2010).
64. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 100(20), 1432-1438 (2008).
65. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31(1), 13-20 (1983).
66. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 8(6), 216 (2006).
67. Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 168(4), 357-363 (1992).
68. Spyratos F, Ferrero-Poüs M, Trassard M et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94(8), 2151-2159 (2002).
69. Viale G, Regan MM, Mastropasqua MG et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuVant chemoendocrine therapy for node-negative breast cancer. J. Natl Cancer Inst. 100(3), 207-212 (2008).
70. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11(2), 174-183 (2010).
71. Yamashita H, Toyama T, Nishio M et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 8(4), R48 (2006).
72. Kai K, Nishimura R, Arima N, Miyayama H, Iwase H. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int. J. Clin. Oncol. 11(6), 426-433 (2006).
73. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99(2), 167-170 (2007).
74. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuVant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12), 1135-1141 (2010).
75. Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr. Opin. Oncol. 22(6), 552-558 (2010).
76. Serrano MJ, Sánchez-Rovira P, Delgado-Rodriguez M, Gaforio JJ. Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer. Cancer Biol. Ther. 8(8), 671-675 (2009).
77. Gaforio JJ, Serrano MJ, Sanchez-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 107(6), 984-990 (2003).
78. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
79. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
80. Von Hoff DD, Stephenson JJ, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28(33), 4877-4883 (2010).
81. Tan SH, Lee SC, Goh BC, Wong J. Pharmacogenetics in breast cancer therapy. Clin. Cancer Res. 14(24), 8027-8041 (2008).
82. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
83. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
84. Lash TL, Lien EA, Sørensen HT, Hamilton- Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10(8), 825-833 (2009).
85. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80(1), 61-74 (2006).
86. Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718-725 (2011).
87. Ma CX, Adjei AA, Salavaggione OE et al. Human aromatase: gene resequencing and functional genomics. Cancer Res. 65(23), 11071-11082 (2005).
88. Colomer R, Monzo M, Tusquets I et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in adVanced breast carcinoma. Clin. Cancer Res. 14(3), 811-816 (2008).
89. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
90. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in adVanced breast cancer patients. Clin. Cancer Res. 12(18), 5496-5502 (2006)